doublewhammy.com

What doublewhammy.com is when you visit it

If you type doublewhammy.com into a browser today, you don’t land on a standalone brand-new website with its own navigation and content library. You get redirected into AbbVie’s SKYRIZI site, specifically a page that talks about the connection between plaque psoriasis (Ps) and psoriatic arthritis (PsA).

So, “doublewhammy.com” is functioning like a vanity domain—a short, memorable address used in advertising that forwards people to a longer page on a main site. In this case, the destination is SKYRIZI.com content aimed at adults with active psoriatic arthritis.

Why the “double whammy” wording shows up in this topic

In everyday English, “double whammy” means two bad things happening at the same time or in sequence.

In psoriasis and PsA education, that phrase gets used because some people deal with skin symptoms (psoriasis) and joint symptoms (psoriatic arthritis). Even when they don’t start together, the conditions are linked, and it can feel like getting hit from two directions.

The SKYRIZI page that doublewhammy.com forwards to leans into that connection and frames it as an awareness point: Ps and PsA are related, but not identical.

What you’ll actually see on the page

The forwarded page is a mix of educational content and brand context. A few key elements stand out:

• It states that “1 in 3” people with plaque psoriasis may also develop PsA, and it describes psoriasis as red/itchy skin patches and PsA as joint pain, stiffness, and swelling.
• It explains the relationship in plain terms: both are chronic, linked to inflammation, but they show up differently—skin vs joints.
• It repeatedly nudges you toward talking with a doctor about symptoms and treatment options.
• It includes Important Safety Information and links out to prescribing information and medication guides (because the destination site is a drug brand website).
• It explicitly notes the site is intended for US residents only, and that the information is not meant to replace a discussion with a healthcare provider.

So if your goal is general disease education, you can still get useful basics there. But you’re reading it in a commercial context, and that matters for how you interpret it.

A more grounded view of the Psoriasis → PsA connection

A lot of campaigns use the “1 in 3” idea because it’s memorable, and it’s broadly consistent with what major patient and clinical organizations say.

The National Psoriasis Foundation describes psoriatic arthritis as affecting about 30% of people with psoriasis, and it also notes that psoriasis often shows up before PsA (though not always).

The NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) explains that most people who develop PsA already have psoriasis, and on average PsA appears years after skin symptoms begin.

And the American Academy of Dermatology makes a practical point that’s easy to miss: there isn’t a perfect way to predict who with psoriasis will develop PsA, which is why noticing swollen or painful joints early is important.

Symptoms people are usually trying to make sense of

If someone ends up on a vanity URL like doublewhammy.com from an ad, they’re often doing quick pattern-matching: “Is what I’m feeling possibly PsA?”

Common symptom descriptions across major clinical references include:

• Joint pain, stiffness, swelling (can affect many joints, sometimes fingers/toes)
• Symptoms that flare and calm down in cycles
• Skin psoriasis and nail changes can be part of the same overall picture

Mayo Clinic summarizes the core symptoms as joint pain, stiffness, and swelling, and emphasizes that treatment aims to reduce symptoms and protect joints.

The important practical point: pain alone isn’t specific. Lots of conditions can look similar early on. That’s why most reputable sources keep repeating the same advice: document symptoms, then bring it to a clinician who can assess the whole story.

How to use a pharma “education” page without getting misled

This is where people either get real value or get frustrated.

Here’s a workable way to approach it:

1. Use it for vocabulary and basic framing. If the page helps you put names on symptoms (skin plaques vs joint swelling), that’s useful.
2. Cross-check the big claims with independent sources. For example, the “about 30% / 1 in 3” relationship is supported by organizations like NPF and is discussed in NIH resources.
3. Treat treatment messaging as a prompt, not a conclusion. Drug-brand sites naturally guide you toward their product ecosystem, support programs, and doctor discussion guides. That doesn’t make the information “fake,” but it does mean it’s selective.
4. Pay attention to the safety and audience notes. The SKYRIZI site makes clear it’s for US residents and isn’t a substitute for medical care.

Privacy and tracking: a quick, realistic note

If you arrived from a TV or online ad, you’re in marketing-land. Sites like this often use cookie banners, “privacy choices,” and tracking infrastructure tied to campaign measurement. The SKYRIZI page includes privacy links and a “Your Privacy Choices” entry, which is a signal that standard ad-tech and compliance mechanisms are in play.

If that bothers you, you can still read the content, but consider:

• using a private window,
• limiting cookies,
• or skipping straight to independent sources (NIH/NIAMS, AAD, Mayo).

Key takeaways

• doublewhammy.com currently redirects to a SKYRIZI.com page about plaque psoriasis and psoriatic arthritis.
• The “double whammy” framing is about skin + joint disease happening in the same person, and the phrase itself means two adverse things at once.
• Major references commonly state around 30% (about 1 in 3) of people with psoriasis may develop psoriatic arthritis.
• The site is health information in a brand context, so it’s best used alongside independent medical sources and clinician advice.

FAQ

Is doublewhammy.com a medical clinic or nonprofit resource?
No. It redirects into a pharmaceutical brand site (SKYRIZI) that provides disease education plus product-related content and safety information.

Is the “1 in 3” Psoriasis-to-PsA claim credible?
It’s broadly consistent with major organizations. The National Psoriasis Foundation discusses PsA affecting about 30% of people with psoriasis, and the SKYRIZI page uses “1 in 3” wording.

Can psoriatic arthritis happen before psoriasis shows up?
Yes, it can. Many people get psoriasis first, but some develop joint symptoms earlier or around the same time.

Should you use the site to self-diagnose?
No. It can help you recognize patterns and prepare questions, but diagnosis requires a clinician evaluation, and multiple conditions can look similar early on.

If I’m not in the US, is the information still relevant?
Some general education may still be useful, but the page explicitly states it’s intended for US residents, and the product/program details may not apply elsewhere.